Related Experiment Videos
Structure-activity relationship in N3-alkyl-xanthine derivatives.
K Takagi1, T Hasegawa, T Kuzuya
1Second Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Japanese Journal of Pharmacology
|April 1, 1988
Summary
Butylxanthine and related compounds show promising bronchodilator effects by inhibiting phosphodiesterase (PDE). Further clinical studies are needed to confirm butylxanthine
Area of Science:
- Pharmacology
- Medicinal Chemistry
Background:
- Xanthine derivatives are explored for their potential therapeutic effects.
- Understanding structure-activity relationships is crucial for drug development.
Purpose of the Study:
- To synthesize and evaluate xanthine derivatives for their relaxant effects on tracheal smooth muscle.
- To assess the inhibitory activity of these derivatives on cyclic adenosine monophosphate phosphodiesterase (c-AMP PDE).
- To compare pharmacokinetic properties and identify potential bronchodilator candidates.
Main Methods:
- Synthesis of N3-substituted xanthine derivatives.
- In vitro evaluation of relaxant effects on guinea pig tracheal smooth muscle.
- In vitro assessment of inhibitory activity against c-AMP PDE.
- Pharmacokinetic studies in rabbits.
Main Results:
- Dose-dependent relaxant effects were observed for the tested xanthine derivatives.
- Propylxanthine, butylxanthine, and isobutylxanthine exhibited comparable relaxant effects.
- Butylxanthine demonstrated potent inhibition of c-AMP PDE, with a strong correlation between alkyl chain length and inhibitory activity (Ki values).
- Pharmacokinetic studies revealed significant differences in half-life, likely influenced by alkyl chain length, but no significant variations in volume of distribution.
Conclusions:
- Alkyl chain length is a critical factor influencing the phosphodiesterase inhibitory activity of N3-substituted xanthine derivatives.
- Butylxanthine emerges as a potential bronchodilator candidate due to its potent PDE inhibition and relaxant effects.
- Further clinical investigations are warranted to evaluate the efficacy and safety of butylxanthine compared to established bronchodilators like theophylline.